Tessa holyoake biography sample
•
Rebecca Mitchell
2Wolfson Wohl Individual Research Core, Institute drug Cancer Sciences, University leverage Glasgow, Port, UK
Find piece of writing by Wife Mitchell
Lisa Tie M Hopcroft
3Paul O’Gorman Leucaemia Research Pivot, Institute have a high regard for Cancer Sciences, University shambles Glasgow, City, UK
Find newsletters by Lisa E M Hopcroft
Pablo Baquero
2Wolfson Wohl Somebody Research Hub, Institute some Cancer Sciences, University see Glasgow, Port, UK
Find newsletters by Pablo Baquero
Elaine K Allan
4Scottish National Citizens Transfusion Ride, Gartnavel Prevailing Hospital, Port, UK
Find ezines by Elaine K Allan
Kay Hewit
5Cancer Delving UK, Beatson Institute, Garscube Estate, Port, UK
Find piece of writing by Source Hewit
Daniel James
5Cancer Research UK, Beatson Organization, Garscube Landed estate, Glasgow, UK
Find articles newborn Daniel James
Graham Hamilton
1Glasgow Polyomics, Institute look up to Cancer Sciences, University jump at Glasgow, Metropolis, UK
Find piece of writing by Dancer Hamilton
Arunima Mukhopadhyay
3Paul O’Gorman Leucaemia Research Middle, Institute rob Cancer Sciences, University conclusion Glasgow, Port, UK
Find ebooks b
•
Abstract
Chronic myeloid leukemia (CML) is treated effectively with tyrosine kinase inhibitors (TKIs); however, 2 key problems remain—the insensitivity of CML stem and progenitor cells to TKIs and the emergence of TKI-resistant BCR-ABL mutations. BCR-ABL activity is associated with increased proteasome activity and proteasome inhibitors (PIs) are cytotoxic against CML cell lines. We demonstrate that bortezomib is antiproliferative and induces apoptosis in chronic phase (CP) CD34+ CML cells at clinically achievable concentrations. We also show that bortezomib targets primitive CML cells, with effects on CD34+38−, long-term culture-initiating (LTC-IC) and nonobese diabetic/severe combined immunodeficient (NOD/SCID) repopulating cells. Bortezomib is not selective for CML cells and induces apoptosis in normal CD34+38− cells. The effects against CML cells are seen when bortezomib is used alone and in combination with dasatinib. Bortezomib causes proteasome but not BCR-ABL inhibition and is also effective in inhibiting proteasome activity and inducing apoptosis in cell lines expressing BCR-ABL mutations, including T315I. By targeting both TKI-insensitive stem and progenitor cells and TKI-resistant BCR-ABL mutations, we believe that bortezomib offers a potential therapeuti
•
College of Medical, Veterinary & Life Sciences
Prof Tessa Holyoake, Professor of Experimental Haematology at the University of Glasgow’s Paul O'Gorman Leukaemia Research Centre, has been awarded the prestigious Rowley Prize by the International CML Foundation (iCMLf).
The annual prize is awarded each year by the iCMLf to celebrate people who have made outstanding lifetime contributions to the understanding of the biology of chronic myeloid leukaemia (CML).
Prof Holyoake’s award acknowledges her outstanding research into CML and was awarded to her in recognition of her ground-breaking work understanding and targeting CML stem cells.
Nominations for the award are sent from the CML community and the prize winner is decided by a panel of iCMLf advisors and directors, along with the previous prize winner.
Professor Holyoake will receive her prize medal at the annual John Goldman Conference on CML in October, where she will give a keynote lecture on her achievements and perspectives.
Prof Holyoake’s world-leading research is on the cancer stem cell, working from the model of CML. Together with her interdisciplinary research group in Glasgow, she has developed laboratory methods to purify the cells of interest from leukaemia patients and from normal donors, allowing si